1. Interferon‐γ‐inducing Factor Gene Transfection into Lewis Lung Carcinoma Cells Reduces Tumorigenicity in vivo
- Author
-
Hirokazu Kurokawa, Hisao Fukumoto, Tomoyuki Ishida, Taisuke Nomoto, Yuji Heike, Yuichiro Ohe, Makoto Nishio, Hitoshi Arioka, Kazuya Fukuoka, Kazuto Nishio, and Nagahiro Saijo
- Subjects
Cancer Research ,animal structures ,DNA, Complementary ,Interferon Inducers ,medicine.medical_treatment ,Spleen ,Biology ,Murine interferon‐γ‐inducing factor ,Transfection ,Article ,Carcinoma, Lewis Lung ,Mice ,In vivo ,medicine ,Animals ,Interferon gamma ,Drug Interactions ,Cells, Cultured ,Interferon inducer ,Interferon‐γ‐ Interleukin‐12 ,Interleukin-18 ,Lewis lung carcinoma ,Virology ,Molecular biology ,Transfectant ,Interleukin-12 ,Recombinant Proteins ,Mice, Inbred C57BL ,Cytokine ,medicine.anatomical_structure ,Oncology ,Interleukin 12 ,Cytokines ,Immunization ,medicine.drug - Abstract
To investigate the immunoregulatory effect of murine interferon-gamma-inducing factor (mIGIF), we transfected Lewis lung carcinoma (LLC) cells with a mammalian expression vector containing the mIGIF complementary DNA. The culture medium of the transfectant cells stimulated interferon-gamma (IFN-gamma) production by spleen cells in vitro in the presence of anti-CD3 antibody and markedly potentiated the effect of interleukin-12 (IL-12) on IFN-gamma production by spleen cells. mIGIF transfectant cells showed reduction of tumorigenicity and induction of an in vivo immuno-protective effect against the parental LLC cells. To examine the combined effect of systemic administration of recombinant IL-12 (rIL-12) and local mIGIF on the tumorigenicity, mice were challenged with LLC or transfectant cells on day 0, and the tumor-bearing mice were injected with 50 ng of rIL-12 intraperitoneally from day 7 to 11. Systemic rIL-12 showed an anti-tumor effect. However, mIGIF gene expression did not potentiate this effect of systemic rIL-12 in vivo.
- Published
- 1997